Journal of Medicinal Chemistry p. 6048 - 6057 (2015)
Update date:2022-08-02
Topics:
Wada, Yasuhiro
Shirahashi, Hiromitsu
Iwanami, Taisuke
Ogawa, Masami
Nakano, Seiji
Morimoto, Akifumi
Kasahara, Ken-Ichi
Tanaka, Eiichi
Takada, Yoshio
Ohashi, Shigeki
Mori, Mutsuhiro
Shuto, Satoshi
Novel indazole derivatives were prepared and evaluated for their biological activity and cardiovascular safety profile as human β3-adrenergic receptor (AR) agonists. Although the initial hit compound 5 exhibited significant β3-AR agonistic activity (EC50 = 21 nM), it also exhibited agonistic activity at the α1A-AR (EC50 = 219 nM, selectivity: α1A/β3 = 10-fold). The major metabolite of 5, which was an oxidative product at the indazole 3-methyl moiety, gave a clue to a strategy for improvement of the selectivity for β3-AR agonistic activity versus α1A-AR agonistic activity. Thus, modification of the 3-substituent of the indazole moiety effectively improved the selectivity to develop compound 11 with potent β3-AR agonistic activity (EC50 = 13 nM) and high selectivity (α1A/β3 = >769-fold). Compound 11 was also inactive toward β1 and β2-ARs and showed dose dependent β3-AR mediated relaxation of marmoset urinary bladder smooth muscle, while it did not obviously affect heart rate or blood pressure (iv, 3 mg/kg) in anesthetized rats.
View MoreXuzhou Tianrun Chemical Co.,Ltd
website:http://www.tianrunchem.cn
Contact:86-516-83832636
Address:fuxing road
Zhejiang Golden-Shell Pharmaceutical Co.,Ltd.
Contact:+86-576-87501888 / 87501988
Address:No.89 Zhongxing Road. Li'ao, Yuhuan, Zhejiang, China
Contact:+86-021-6989-5597
Address:No.80 Yichuan Rd., Putuo District,Shanghai,P.R.China
Contact:+86-0512-62857507
Address:Boji Science Park, No1688C,Taishan road, Suzhou ,China
Shenyang NovPharm Technology Co., Ltd.
Contact:.+86-24-24165786
Address:Room 306, Hongjin Mansion, No. 36-1, Wanliutang Rd., Shenhe District, Shenyang, Liaoning, P.R.C.
Doi:10.1021/ma100501j
(2010)Doi:10.1021/jm201157c
(2012)Doi:10.1007/s00044-010-9303-8
(2011)Doi:10.1002/hlca.19590420320
(1959)Doi:10.1016/j.bmcl.2014.02.026
(2014)Doi:10.1007/BF00957199
(1989)